Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care

Core Insights - Natera, Inc. has announced the publication of a new prospective clinical trial in Transplantation Direct, focusing on donor-derived cell-free DNA (dd-cfDNA) surveillance [1] - The study was conducted by The Ohio State University Wexner Medical Center (OSU-WMC) to evaluate whether Prospera-guided monitoring can reduce the number of invasive biopsies for patients [1] Company Overview - Natera, Inc. is recognized as a global leader in cell-free DNA and precision medicine [1] - The company is actively involved in advancing non-invasive monitoring techniques in the field of transplantation [1] Industry Context - The trial aims to enhance patient care by potentially minimizing the need for invasive procedures, which is a significant concern in transplantation medicine [1] - The use of dd-cfDNA surveillance represents a growing trend in precision medicine, emphasizing the importance of non-invasive diagnostic methods [1]